Three pharma stocks that stand to benefit from the announcement by Eli Lilly & Co. (LLY) and Incyte (INCY)  that the FDA rejected their rheumatoid arthritis pill baricitinib were up Monday.

Gilead Sciences (GILD) shares rose 56 cents in early trading Monday to $67.06 while Pfizer  (PFE) was up 9 cents to $33.97 and Abbvie (ABBV) up 38 cents to $64.51.

In a statement Friday, Lilly said the FDA has requested additional clinical data to determine appropriate doses of baricitinib. The FDA also asked for more safety data.

Baricitinib was expected to secure U.S. approval and deliver $2 billion or more in peak sales as the most effective, once-daily oral JAK inhibitor for rheumatoid arthritis, supplanting Pfizer's Xeljanz. Lilly was counting on the greater efficacy of a higher baricitinib dose to separate from Xeljanz. If Lilly can only move forward with a lower, 2 mg dose of baricitinib, it risks losing an efficacy advantage over its oral JAK inhibitor competitor.

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year maybe even longer.

Gilead wins because its oral JAK inhibitor filgotinib -- currently in a phase III study for rheumatoid arthritis, among other indications -- has a good chance to catch up.

As marketers of TNF inhibitor injections for rheumatoid arthritis, Abbvie, Amgen (AMGN) and Johnson & Johnson  (JNJ) all win from the delay of another oral competitor.

Lastly, Regeneron Pharma ( REGN) and Sanofi ( SNY) win because they'll now have more time to establish a marketing presence for their IL-6 inhibitor sarilumab, assuming the injected drug can overcome a manufacturing delay and win FDA approval later this year.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Regulation

Bitcoin Today: Prices Come Off Highs as Rally to $10,000 Pauses

Bitcoin Today: Prices Come Off Highs as Rally to $10,000 Pauses

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

BeyondSpring CEO Reveals Novel Tumor Therapy

BeyondSpring CEO Reveals Novel Tumor Therapy

Bitcoin Today: Prices Surge Past $9,000 Mark as Rally Continues

Bitcoin Today: Prices Surge Past $9,000 Mark as Rally Continues

NXP Semiconductors Plunges as Qualcomm Deal Doubts Resurface

NXP Semiconductors Plunges as Qualcomm Deal Doubts Resurface